Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
About Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.
Core Business and Product Portfolio
At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.
In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.
Technological Innovation: The DETERx® Platform
Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.
Strategic Growth and Market Position
Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.
With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.
Commitment to Responsible Pain Management
Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.
Conclusion
Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced 11 poster presentations at the Annual PAINWeek National Conference from September 6-9, 2022, in Las Vegas. These presentations showcase data on its differentiated products, particularly Xtampza® ER and Celecoxib Oral Solution. Dr. Thomas Smith highlighted the opportunity to share clinical insights, emphasizing the company's commitment to enhancing patient care for serious medical conditions. The research details the efficacy and safety of treatments while addressing risks like addiction and cardiovascular issues associated with their products.
Collegium Pharmaceutical reported record net revenue of $123.5 million for Q2 2022, a significant increase from $82.9 million in Q2 2021. Following the BDSI acquisition, the company completed phase one of its integration and is on track to exceed targeted synergies of at least $75 million. Full-year adjusted EBITDA guidance has been raised to between $245 million and $255 million. However, the company posted a net loss of $5.2 million, or $0.15 per share, compared to a net income of $72.8 million in the same quarter last year.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will announce its Q2 2022 financial results on August 4, 2022, after market closure. A corresponding conference call will be held at 4:30 p.m. ET, allowing investors to discuss the financial outcomes live. To participate, dial (877) 407-8037 for U.S. callers or (201) 689-8037 internationally, referencing the 'Collegium Pharmaceutical Q2 2022 Earnings Call.' An audio webcast will also be available on the company's website, with a replay accessible two hours post-event.
Collegium Pharmaceutical (Nasdaq: COLL) announced its participation at the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. Collegium’s presentation is set for May 24, 2022, at 3:30 pm ET. The company is focused on improving the lives of those with serious medical conditions and is headquartered in Stoughton, Massachusetts. For more information, visit www.collegiumpharma.com.
Collegium Pharmaceuticals reported Q1 2022 net revenue of $83.8 million, down from $87.7 million in Q1 2021. The BDSI acquisition is on track to exceed targeted run rate synergies of $75 million. The company has resolved all opioid-related litigation and provided financial guidance for 2022, expecting revenues between $450 million and $465 million. Despite a net loss of $13.1 million this quarter, Collegium’s outlook remains positive with a cash balance of $106.7 million.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call on May 10, 2022, at 4:30 p.m. ET, to discuss its Q1 2022 financial results and provide a corporate update. Interested parties can join by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international callers. The call will also be available via a live audio webcast on the company’s website, with replays accessible two hours after the event.
Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical (Nasdaq: COLL) announced its participation in the 21st Annual Needham Virtual Healthcare Conference, set for April 13, 2022. Management will engage in a virtual fireside chat, which will be webcast and accessible through the investor section of the company's website. A replay will be available for 30 days following the event. Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts. For more details, visit www.collegiumpharma.com.
Collegium Pharmaceutical (Nasdaq: COLL) announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. McFarlane brings extensive experience from previous leadership roles at Adamas Pharmaceuticals and Retrophin. The Chairman, Mike Heffernan, expressed confidence in McFarlane's ability to provide valuable insights and contributions. This strategic addition comes as the company aims to enhance its operations and improve the lives of individuals with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has updated its financial guidance for 2022 following the acquisition of BioDelivery Sciences International on March 22, 2022. Expected total product revenues are projected between $450.0 million and $465.0 million, reflecting a 65% increase from $276.9 million in 2021. Adjusted operating expenses are estimated at $130.0 million to $140.0 million and adjusted EBITDA is expected to reach $235.0 million to $250.0 million. The company aims for operational synergies of at least $75 million as it integrates BDSI.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has reached a Master Settlement Agreement to resolve 27 opioid-related lawsuits without admitting liability. Executed on March 18, 2022, the company has paid $2.75 million to the plaintiffs, leading to case dismissals anticipated in the upcoming weeks. This settlement follows a previously announced framework from December 2021, marking a strategic decision to mitigate legal risks. Collegium aims to strengthen its position as a specialty pharmaceutical company focused on aiding patients with serious medical conditions.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What does Collegium Pharmaceutical Inc. specialize in?
What is the DETERx® technology platform?
What are Collegium’s key products?
How does Collegium address opioid misuse and abuse?
What was the significance of the Ironshore Therapeutics acquisition?
Where is Collegium Pharmaceutical headquartered?
How does Collegium differentiate itself in the pharmaceutical industry?
What markets does Collegium operate in?
